Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences |
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, CA, 92121
USA
Press release date: September 7, 2010
SAN DIEGO, Sept. 7, 2010 -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 10:55 a.m. ET / 7:55 a.m. PT in New York, and at the Baird Global Healthcare Conference on Tuesday, September 14, 2010 at 11:30 a.m. ET / 8:30 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Morgan Stanley conference. Alex Casdin, vice president, finance of Amylin, will provide a corporate overview at the Baird conference.
The presentations will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com, and the recordings will be made available on the Web site following the events. To access the live webcasts, please log on to Amylin's Web site approximately fifteen minutes prior to the presentations to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.
Source: Amylin Pharmaceuticals, Inc.
CONTACT: Michael York, Senior Director, Investor Relations, ext. 8602, or Alice Izzo, Vice President, Corporate Affairs, ext. 7272, both of Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web Site: http://www.amylin.com/
|
|
|
|
|
|
|
|
|
|
|
| 
